Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated ...
Researchers found that sargramostim decreased UCH-L1 and total tau levels in mild-to-moderate Alzheimer’s patients. MMSE ...
Could a simple blood test predict your risk of getting dementia years, or even decades, before you experience memory loss?
The combined Mediterranean and blood pressure lowering diet may slow the structural changes related to brain aging, finds new ...
Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC – an emerging PD biomarker) at baseline with a reduction ...
Living brain tissue can now be made transparent, helping scientists see deeper neurons while keeping cells active.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the 'Company'), a clinical-stage biopharmaceutical company focused on its Phase ...
A new study found combining the Mediterranean diet and the Dietary Approaches to Stop Hypertension reduces the odds of heart ...
Nektar Therapeutics (Nasdaq: NKTR) announced today that data from the ongoing Phase 2b studies of rezpegaldesleukin in atopic ...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated ...
Two large phase 3 trials found that oral semaglutide 14 mg did not slow cognitive or functional decline over 104 weeks in ...
A long-running study suggests that the MIND diet may be linked to slower structural brain changes that often accompany aging.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results